Co-Author of the Karolinska 1000 Consecutive MANTA® Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

WAYNE, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that Dr. Magnus Settergren*, Asssociate Professor at the Karolinska Institutet, Interventional Cardiologist at Karolinska University Hospital, and Co-Author of the Percutaneous plug-based vascular closure device in 1000 consecutive transfemoral transcatheter aortic valve implantations Study, is scheduled to present at a Teleflex-sponsored Training Pavilion at the Transcatheter Cardiovascular Therapeutics (TCT) conference this Sunday, September 18, 2022 at 10:00 a.m. (ET). TCT is the annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine.

The Karolinska 1000 Consecutive MANTA^® Device Study—the largest ever real-world evaluation of the MANTA^® Device—demonstrated safety and effectiveness with low complication rates and a short learning curve.¹ Results of this study were published in .

This single-center, observational study reviewed 1048 consecutive, unselected subjects undergoing transfemoral Transcatheter Aortic Valve Implantation (TAVI) from May 2017 to September 2020 at the Karolinska University Hospital in Stockholm, Sweden. The 18 French MANTA^® Device was used by five operators to close the femoral artery access site in 1000 subjects (48 excluded), with the primary outcome being the measure of vascular closure device (VCD)-related major complications according to Valve Academic Research Consortium (VARC)-2 definition criteria.¹

The study, which was not sponsored by Teleflex, demonstrated that MANTA^® Device related major vascular complications occurred in 4.2% of patients with no significant differences in preoperative characteristics between patients with and without MANTA^® Device related major vascular complication.¹ This outcome is consistent with the results of the SAFE MANTA IDE Clinical Trial, published in 2019 in , which demonstrated a 4.2% VARC-2 Major Vascular Complication Rate, as well as The MARVEL Prospective Registry, published in 2020 in , which demonstrated a 4.0% VARC-2 Major Vascular Complication Rate.^2,3

“As interventionalists, we frequently hear that one of the argued benefits of the MANTA^® Device compared to suture-based VCDs is a comparatively shorter learning curve; however, few studies have included a learning curve analysis,” said Dr. Settergren. “Our study found no significant differences in major complications between interventionalists, whether in their first 20 MANTA^® Device deployments, or even across the the first 100 procedures at the center.”

“The findings of our study indicate that the MANTA^® Device is easy to learn and has a short learning curve, which is in line with our user experience. I look forward to presenting our learnings from this real-world experience to my colleagues at TCT this weekend,” concluded Dr. Settergren.

About the MANTA^® Vascular Closure Device

The MANTA^® Device is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure. The MANTA^® Device has now sold 100,000 units globally with 6+ years of commercial clinical experience. The device has been studied in 35+ clinical studies—25 focused on TAVI/TAVR.⁴

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit .

Teleflex is the home of Arrow^®, Deknatel^®, LMA^®, Pilling^®, QuikClot^®, Rusch^®, UroLift^®, and Weck^® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, MANTA, Pilling, QuikClot, Rusch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2022 Teleflex Incorporated. All rights reserved. MC-008393 Rev 0

*Dr. Settergren is a paid consultant of Teleflex Incorporated.

References:

1. Kastengren, M, Settergren, M, et al. Percutaneous plug-based vascular closure device in 1000 consecutive transfemoral transcatheter aortic valve implantations. International Journal of Cardiology. 2022; Vol 359. /10.1016/j.ijcard.2022.04.033
2. The SAFE MANTA IDE Clinical Trial. Study sponsored by Teleflex Incorporated or its affliates.
3. Kroon HG, Tonino PAL, Savontaus M, et al. Dedicated plug based closure for large bore access –The MARVEL prospective registry. Catheter Cardiovasc Interv. 2020;1–9.
4. Data on file at Teleflex.

Contacts:

For Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

John Hsu, CFA

Vice President, Investor Relations

610-948-2836

Source:

Teleflex Incorporated